欧洲每年新诊断出的前列腺癌有 850 0 0例 ,占男性癌患者的 13% ,近 50 %的患者在确诊时已浸润到骨组织。在这些病例中 ,抑制雄激素活性被认为是最适当的一线治疗 ,但激素治疗的有效率只有 6 0 %～ 80 % ,平均有效期12～ 18个月。病情复发和对激素耐药的患者因骨痛和生存期短而 In Europe, there are 850 new cases of prostate cancer diagnosed every year, accounting for 13% of male cancer patients. Nearly 50% of patients have infiltrated bone tissue at the time of diagnosis. In these cases, inhibition of androgen activity is considered the most appropriate first-line treatment, but the effective rate of hormone therapy is only 60% to 80%, and the average effective period is 12 to 18 months. Patients with relapsed and hormone-resistant patients suffer from bone pain and short survival